The Preclinical Evaluation of Fever-Range, Whole Body Hyperthermia as an Adjuvant to Chemotherapy and Cytokine Immunotherapy for the Treatment of Breast Cancer
Annual rept. 1 Jun 1999-31 May 2000
HEALTH RESEARCH INC BUFFALO NY
Pagination or Media Count:
The work outlined in the original grant proposal was designed to develop new breast cancer treatments that combined a current breast cancer chemotherapy doxorubicin and Doxil and a cytokine-based immunotherapy IL-l2 and IL-2 with fever-like whole body hyperthermia WBH. We have found that the combination of WBH with Doxil does indeed result in a better anti-tumor effect in our SCID mouse human breast tumor xenograft model when compared to Doxil alone. Experiments examining free Doxorubicin are underway. Additional work has shown that free lL-l2 when used in combination with WBH only marginally enhances the anti- tumor response when compared to the IL-l2 alone in our model. We feel that this is due to the lack of T and B cells in the SCID mice that may have inhibited our cytokine immunotherapy protocol. Therefore additional experiments have been executed using a different model BALEc mice bearing Colon 26 tumors while a more appropriate breast cancer model can be developed. Data using this model have been extremely promising when using both free IL-l2 and polylactic acid microsphere encapsulated IL-l2. Overall, the results generated the past year have been promising.
- Anatomy and Physiology
- Medicine and Medical Research